好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Bilateral Vestibulopathy: Strong Association With the ZNF91/LINC01224 Locus
Neuro-ophthalmology/Neuro-otology
S18 - Neuro-ophthalmology/Neuro-otology (4:18 PM-4:30 PM)
005

A genome-wide association study (GWAS) was done in patients with idiopathic bilateral vestibulopathy (BVP) to identify underlying genetic causes.

Known etiologies of BVP are, e.g., ototoxic exposure, bilateral Menière’s disease, and genetic syndromes including RFC1-related disorders and FGF14-GAA-Ataxia (SCA27b). While these discoveries highlight monogenic contributions, they explain only a minority of cases, leaving a substantial proportion idiopathic. 

We analyzed a European cohort of 132 individuals diagnosed with idiopathic BVP and 3,410 unaffected controls. Demographic and clinical data were collected from affected individuals.  Diagnosis was based on the current diagnostic criteria of the Bárány Society. Following quality control and removal of outliers, genome-wide association was performed on approximately 7.5 million variants, complemented by gene-based analysis with MAGMA.

GWAS identified two loci reaching genome-wide significance. The strongest signal mapped to chromosome 19 (ZNF91/LINC01224), with rs12185481 (p = 3.60E-16) as the lead variant. A second, more tentative signal emerged on chromosome 2 represented by rs73006457 (p = 4.46E-08) with GPC1 and OTOS as the nearest candidate genes. Gene-based analysis revealed six significant loci, including ZNF91, highlighting novel candidate genes with potential relevance to BVP pathogenesis.

This study provides novel insights into the genetic basis of previously idiopathic BVP, pointing to ZNF91/LINC01224 as a major contributor. The association of this locus suggests a functional link between transcriptional regulation, retrotransposon silencing, and vestibular pathology with age-related decline in ZNF91 expression potentially amplifying genetic risk and aligning with the typical mid-to late-adult onset of BVP. The second locus near OTOS on chromosome 2 represents a less robust, though pathophysiologically plausible candidate, as OTOS is expressed in the inner ear and has previously been associated with susceptibility to ototoxic-induced hearing loss. Together, these findings highlight novel pathways in BVP pathogenesis and merit replication in larger, independent cohorts.

Authors/Disclosures
Michael Strupp, MD, DO, FAAN (Hospital of the Ludwig Maximilians University, Munich, Dept of Neurology)
PRESENTER
Dr. Strupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertify. Dr. Strupp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for IntraBio. Dr. Strupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vifor, Frisenius, CH. Dr. Strupp has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Strupp has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers. Dr. Strupp has stock in IntraBio.
Felix Heindl Felix Heindl has nothing to disclose.
Andreas Zwergal, MD Prof. Zwergal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dr. Willmar Schwabe GmbH. Prof. Zwergal has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Dr. Willmar Schwabe GmbH. Prof. Zwergal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Astra Zeneca. Prof. Zwergal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. The institution of Prof. Zwergal has received research support from Dr. Willmar Schwabe GmbH. The institution of Prof. Zwergal has received research support from Cures Within Reach.
Annette Hartmann (Medical University of Vienna) Annette Hartmann has nothing to disclose.
Dan Rujescu Dan Rujescu has nothing to disclose.